Early clinical trial data show that a topical drug called mecamylamine is safe to use and can slow the progress of a severe form of eye disease in people with type 1 diabetes. Because this potential treatment can be self-administered, it may also ease the burdens of healthcare costs and compliance.
The latest data on a gene therapy developed by a JDRF industry partner reveal its potential to stimulate nerve regrowth in the legs, offering hope to people suffering from diabetic neuropathy.
Certain drugs currently used to treat high blood pressure appear to significantly slow the progression of diabetic retinopathy.
The study shows that lipid levels may be involved in the development of diabetes and diabetic complications. It raises questions about the need for lipid monitoring and management in type 1 diabetes as a way to prevent complications beyond cardiovascular disease.
By Catherine Marschilok, M.S.N., C.D.E., Board Certified in Advanced Diabetes Management We all know a diagnosis of type 1 diabetes (T1D) is hard on families as they learn to cope with a number of changes in their daily life. While people care, it is all too common for them to ask questions that reflect a […]
The finding offers an important clue about the genetics of diabetic nephropathy and may contribute to the development of targeted preventive therapies or new therapeutic targets.
A promising treatment called SB-509, for a form of diabetic neuropathy that affects nerve cells in the legs, is being evaluated in a Phase 2 clinical trial.